Clinical Evaluation of Some Local Antimicrobial Agents' Adjunctive Effects On Periodontal Parameters and Halitosis

NCT03468595 — Not applicable, Completed, 90 participants, Near East University, Turkey

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical Evaluation of Some Local Antimicrobial Agents' Adjunctive Effects On Periodontal Parameters and Halitosis With Subgingival Ultrasonic Instrumentation in Periodontitis Patients: A Randomized Clinical Study

RegistryNCT03468595
StatusCompleted
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: single, supportive care
Enrollment90 (Actual)
SponsorNear East University, Turkey (Other)
ConditionsHalitosis
Interventionsultrasonic (Piezon Master 700) performed with Listerine, ultrasonic (Piezon Master 700) performed with CHX, ultrasonic (Piezon Master 700) performed with serum (Device)
Datesstart 2016-03-01, primary completion 2016-09-01, completion 2017-05-01, first posted 2018-03-16, last updated 2018-03-16

Related Papers Related Patents Related Grants Related Experts
All trials for Halitosis All trials of ultrasonic (Piezon Master 700) performed with Listerine All trials of ultrasonic (Piezon Master 700) performed with CHX

-Summary

The aim of this trial was to establish the clinical efficacy of Listerine and chlorhexidine (CHX) when used as a cooling agent with ultrasonic instrumentation, on periodontal parameters and halitosis.

Ninety patients with periodontal disease participated for the study. Individuals were randomly selected to a control and test groups. At baseline, all subjects completed a questionnaire and carried out an examination. Standard periodontal outcome variables were assessed. For both groups, the plaque index (PI), gingival index (GI), pocket depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL) scores were enrolled at baseline and after 30 days. Volatile sulphur compound (VSC) levels were evaluated by a Halimeter (Interscan Corp., Chatsworth, CA, USA) at baseline (T0), immediately after treatment (T1), and at 7 (T2), 14 (T3) and 30 days (T4).

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
test 1ExperimentalDevice: ultrasonic (Piezon Master 700) performed with CHXThe treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
test 2ExperimentalDevice: ultrasonic (Piezon Master 700) performed with ListerineThe treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson \& Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
controlActive comparatorDevice: ultrasonic (Piezon Master 700) performed with serumThe treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
  • ultrasonic (Piezon Master 700) performed with Listerine (Device), also known as EMS, Nyon
  • ultrasonic (Piezon Master 700) performed with CHX (Device), also known as EMS, Nyon
  • ultrasonic (Piezon Master 700) performed with serum (Device), also known as EMS, Nyon

+Outcome measures

Primary outcomes

  • Periodontal Pocket Depth (PPD) [30 day]: PD were evaluated: at the follow-up sessions by the investigator with by marking a point on a 10 mm periodontal probe.

Secondary outcomes

  • halimeter values [30 day]: The changes of Volatile Sulphure Compaunds by were evaluated with Halimeter Device at the follow-up sessions by the investigator. The Halimeter reads out in parts-per-billion (ppb) of volatile sulfur compounds.

+Eligibility

Sex: All, ages: 20 Years to 80 Years, accepts healthy volunteers

Inclusion Criteria:

* In the present trial, who had periodontitis from patients undergoing periodontal treatment at the Department of Periodontology of our institution

Exclusion Criteria:

* Individuals who presented any systemic disorders which cause halitosis (diabetes mellitus, nephropathy, liver disease, gastrointestinal diseases, respiratory problems), pregnancy or lactation, individuals who had taken antibiotics over the last 6 months or permanently used any drugs, individuals who had any form of periodontal treatment within 6 months prior to the study.

+Investigators

  • Hasan Guney YILMAZ, DDS, PhD, Study director, Near East University, Faculty of Dentistry